Neurodegenerative Disease News and Research

RSS

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

Repligen Corporation today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).

16 Dec 2009

Scientists explore new strategies for treating neurodegenerative diseases

Studies with fruit flies have shown that the specialized nerve cells called neurons can rebuild themselves after injury.

7 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

A leader in the fight against brain diseases and in drug discovery joins UF

A leader in the fight against brain diseases and in drug discovery to help Alzheimer's patients has joined the University of Florida College of Medicine, interim dean Michael Good, M.D., announced.

2 Dec 2009

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

Groundbreaking discovery provides fundamental insights into neurological disorders

Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School and neurologist at the Massachusetts General Hospital in Boston, on Thursday, November 19, presented his laboratory's research on the new field of study called "Connectivity" at the launch of the MINDlink Foundation.

21 Nov 2009

Alzheimer Research Forum reports on the highlights of the Society of Neuroscience conference

Between 17-21 October 2009, the 39th annual conference of the Society of Neuroscience drew some 30,500 people to the great city of Chicago, which was more balmy than windy for the occasion. Your Alzforum reporters have been busy roaming the halls, buttonholing scientists for their comments on the presentations, and putting together reports on the most significant advances.

20 Nov 2009

Neuralstem provides financial and business updates for third-quarter 2009

Neuralstem, Inc. today provided a financial and business update for the third quarter ended September 30, 2009.

17 Nov 2009

Study establishes link between smoking and Amyotrophic Lateral Sclerosis

While previous studies have indicated a "probable" connection between smoking and ALS, a new study published in the Nov. 17, 2009 issue of Neurology-, the medical journal of the American Academy of Neurology, states that smoking may now be considered an "established" risk factor for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

17 Nov 2009

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD). The research, published by Cell Press in the November 12 issue of the journal Neuron, finds that the novel gene interacts with a key cellular enzyme previously linked with AD pathology, thereby uncovering a new strategy for treating this devastating disorder.

12 Nov 2009

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.

12 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.

30 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

Intellectual property covering compounds that have utility in treating SMA licensed

Repligen Corporation announced today that it has entered into an exclusive license agreement with Families of Spinal Muscular Atrophy (FSMA) for intellectual property covering compounds which may have utility in treating Spinal Muscular Atrophy (SMA).

23 Oct 2009

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

20 Oct 2009

NIH awards a $2.2M grant to biochemist for a high-resolution electron microscope

Waltham, MA-Researchers' ability to rapidly detect the macromolecular protein clumps implicated in Alzheimer's and other neurodegenerative diseases will soon get a sizable boost in the lab of biochemist and Howard Hughes Medical Investigator Nikolaus Grigorieff. The National Institutes of Health has just awarded Grigorieff a $2.2 million grant for a second high-resolution electron microscope (EM) in his lab.

8 Oct 2009

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

7 Oct 2009

Neurodegenerative Disease News and Research

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

Scientists explore new strategies for treating neurodegenerative diseases

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

A leader in the fight against brain diseases and in drug discovery joins UF

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

Groundbreaking discovery provides fundamental insights into neurological disorders

Alzheimer Research Forum reports on the highlights of the Society of Neuroscience conference

Neuralstem provides financial and business updates for third-quarter 2009

Study establishes link between smoking and Amyotrophic Lateral Sclerosis

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Researchers show Simvastatin prevents Parkinson's disease from progressing further

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

Intellectual property covering compounds that have utility in treating SMA licensed

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

NIH awards a $2.2M grant to biochemist for a high-resolution electron microscope

HDSA honors outstanding contributors against Huntington's Disease

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News